Peripheral neuropathy associated with levodopa–carbidopa intestinal infusion: a long‐term prospective assessment

Subacute and chronic peripheral neuropathies (PNP) have been reported in Parkinson's disease (PD) patients treated with levodopa/carbidopa intestinal gel infusion (LCIG), although several aspects of their incidence and pathogenesis still remain to be clarified. This study main objective is to prospectively report the 2‐year incidence of PNP in patients treated with LCIG.

[1]  V. Fung,et al.  Levodopa-Carbidopa Intestinal Gel in Advanced Parkinson'd Disease: Final 12-Month, Open-Label Results , 2014, Movement disorders : official journal of the Movement Disorder Society.

[2]  M. Onofrj,et al.  Polyneuropathy associated with duodenal infusion of levodopa in Parkinson's disease: features, pathogenesis and management , 2014, Journal of Neurology, Neurosurgery & Psychiatry.

[3]  J. Volkmann,et al.  Cutaneous neuropathy in Parkinson’s disease: a window into brain pathology , 2014, Acta Neuropathologica.

[4]  K. Kieburtz,et al.  Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study , 2014, The Lancet Neurology.

[5]  M. Rizzone,et al.  Levodopa/carbidopa intestinal gel infusion in advanced Parkinson's disease: a 7‐year experience , 2014, European journal of neurology.

[6]  F. Carrillo,et al.  Long-term levodopa/carbidopa intestinal gel in advanced Parkinson’s disease , 2014, Journal of Neurology.

[7]  M. Rizzone,et al.  Prospective assessment of peripheral neuropathy in Duodopa‐treated parkinsonian patients , 2014, Acta neurologica Scandinavica.

[8]  P. Barone,et al.  Neuropathy and levodopa in Parkinson's disease: Evidence from a multicenter study , 2013, Movement disorders : official journal of the Movement Disorder Society.

[9]  F. Ehlen,et al.  Neuropathy in Parkinson’s Disease Patients with Intestinal Levodopa Infusion versus Oral Drugs , 2013, PloS one.

[10]  G. Ebersbach,et al.  Peripheral neuropathy in Parkinson's disease: levodopa exposure and implications for duodenal delivery. , 2013, Parkinsonism & related disorders.

[11]  D. Nyholm,et al.  Levodopa/carbidopa intestinal gel infusion long‐term therapy in advanced Parkinson’s disease , 2012, European journal of neurology.

[12]  G. Jensen,et al.  Consensus statement: Academy of Nutrition and Dietetics and American Society for Parenteral and Enteral Nutrition: characteristics recommended for the identification and documentation of adult malnutrition (undernutrition). , 2012, JPEN. Journal of parenteral and enteral nutrition.

[13]  P. Calabresi,et al.  Coenzyme Q10, Hyperhomocysteinemia and MTHFR C677T Polymorphism in Levodopa-treated Parkinson’s Disease Patients , 2012, NeuroMolecular Medicine.

[14]  F. Valldeoriola,et al.  Polyneuropathy while on duodenal levodopa infusion in Parkinson’s disease patients: we must be alert , 2012, Journal of Neurology.

[15]  R. Freeman,et al.  Diabetic Neuropathies: Update on Definitions, Diagnostic Criteria, Estimation of Severity, and Treatments , 2010, Diabetes Care.

[16]  S. Wiebe,et al.  Levodopa, methylmalonic acid, and neuropathy in idiopathic Parkinson disease , 2010, Annals of neurology.

[17]  S. Harik,et al.  Neurologic complications of gastric bypass surgery for morbid obesity , 2007, Neurology.

[18]  R. Hughes,et al.  A modified peripheral neuropathy scale: the Overall Neuropathy Limitations Scale , 2006, Journal of Neurology, Neurosurgery & Psychiatry.

[19]  W. Kuhn,et al.  Levodopa-associated increase of homocysteine levels and sural axonal neurodegeneration. , 2004, Archives of neurology.

[20]  R. Buschbacher,et al.  Electrodiagnosis in Diseases of Nerve and Muscle: Principles and Practice, 3rd Edition , 2003 .

[21]  Merkies Is,et al.  Psychometric evaluation of a new sensory scale in immune-mediated polyneuropathies. Inflammatory Neuropathy Cause and Treatment (INCAT) Group. , 2000 .

[22]  P. V. van Doorn,et al.  Psychometric evaluation of a new sensory scale in immune-mediated polyneuropathies , 2000, Neurology.

[23]  P. Schmitz,et al.  Interobserver agreement in the assessment of muscle strength and functional abilities in Guillain‐Barré syndrome , 1991, Muscle & nerve.

[24]  Ronald S. Sims,et al.  Neuroimmune Networks , 1990, Neurology.

[25]  A. Kupsch,et al.  Guillain-Barre/CIDP-like neuropathy in two parkinsonian patients following intestinal levodopa/carbidopa treatment. , 2014, Parkinsonism & related disorders.

[26]  A. Antonini,et al.  Prevalence and features of peripheral neuropathy in Parkinson's disease patients under different therapeutic regimens. , 2014, Parkinsonism & related disorders.

[27]  C. Mazia.  Neuropathy in Parkinson disease: Prevalence and determinants , 2012 .

[28]  M. Rizzone,et al.  Long-term duodenal levodopa infusion in Parkinson’s disease: a 3-year motor and cognitive follow-up study , 2012, Journal of Neurology.

[29]  A. Bonnet,et al.  [The Unified Parkinson's Disease Rating Scale]. , 2000, Revue neurologique.

[30]  S. Fahn.  Members of the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale , 1987 .